	US 12,187,730 B2
	Salts of TAM inhibitors
Zhongjiang Jia, Kennett Square, PA (US); Yongzhong Wu, Glen Mills, PA (US); Yongchun Pan, Wilmington, DE (US); Jiacheng Zhou, Newark, DE (US); and Qun Li, Newark, DE (US)
Assigned to Incyte Corporation, Wilmington, DE (US)
Filed by Incyte Corporation, Wilmington, DE (US)
Filed on Aug. 13, 2021, as Appl. No. 17/401,570.
Application 17/401,570 is a division of application No. 16/823,751, filed on Mar. 19, 2020, granted, now 11,104,682.
Application 16/823,751 is a division of application No. 16/142,514, filed on Sep. 26, 2018, granted, now 10,633,387, issued on Apr. 28, 2020.
Claims priority of provisional application 62/714,196, filed on Aug. 3, 2018.
Claims priority of provisional application 62/564,070, filed on Sep. 27, 2017.
Prior Publication US 2022/0227770 A1, Jul. 21, 2022
Int. Cl. A61P 35/00 (2006.01); C07D 487/04 (2006.01)

CPC C07D 487/04 (2013.01) [A61P 35/00 (2018.01); C07B 2200/13 (2013.01)]

30 Claims

1. A method for treating a cancer in a patient, said method comprising: administering to the patient a therapeutically effective amount of a salt which is N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl) pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide maleic acid salt, wherein the cancer is selected from lung cancer, prostate cancer, colon cancer, breast cancer, melanoma, renal cell carcinoma, gastric cancer, rhabdomyosarcoma, glioblastoma, endometrial cancer, ovarian cancer, Kaposi sarcoma, esophageal cancer, pancreatic cancer, thyroid cancer, osteosarcoma, and hepatocellular cancer; and wherein the cancer is associated with abnormal expression or activity of a TAM kinase.